Andrew Hill Investment Advisors Inc. Buys 32 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Andrew Hill Investment Advisors Inc. lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,954 shares of the pharmaceutical company’s stock after purchasing an additional 32 shares during the quarter. Vertex Pharmaceuticals accounts for 3.5% of Andrew Hill Investment Advisors Inc.’s holdings, making the stock its 10th biggest holding. Andrew Hill Investment Advisors Inc.’s holdings in Vertex Pharmaceuticals were worth $4,197,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Capital World Investors lifted its position in shares of Vertex Pharmaceuticals by 17.2% during the 1st quarter. Capital World Investors now owns 25,567,184 shares of the pharmaceutical company’s stock worth $10,687,339,000 after buying an additional 3,761,414 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Vertex Pharmaceuticals by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 22,676,518 shares of the pharmaceutical company’s stock worth $9,479,011,000 after buying an additional 394,338 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Vertex Pharmaceuticals by 61.0% during the 1st quarter. Capital Research Global Investors now owns 5,743,882 shares of the pharmaceutical company’s stock worth $2,401,000,000 after buying an additional 2,176,218 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Vertex Pharmaceuticals by 21.2% during the 1st quarter. Jennison Associates LLC now owns 4,782,374 shares of the pharmaceutical company’s stock worth $1,999,080,000 after buying an additional 837,461 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth $1,237,877,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock traded down $3.94 during trading on Monday, reaching $464.51. 828,389 shares of the company’s stock traded hands, compared to its average volume of 1,220,278. Vertex Pharmaceuticals Incorporated has a 1 year low of $340.83 and a 1 year high of $510.64. The company has a market capitalization of $119.89 billion, a P/E ratio of 30.08 and a beta of 0.39. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average is $481.41 and its 200 day moving average is $441.05.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The firm had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. During the same quarter in the prior year, the company earned $3.53 earnings per share. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current year.

Analyst Ratings Changes

VRTX has been the subject of several research reports. Truist Financial reiterated a “buy” rating and issued a $550.00 target price (up from $508.00) on shares of Vertex Pharmaceuticals in a research report on Monday, August 5th. Morgan Stanley raised their price objective on Vertex Pharmaceuticals from $402.00 to $455.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 11th. JPMorgan Chase & Co. raised their price objective on Vertex Pharmaceuticals from $505.00 to $510.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Argus raised their price objective on Vertex Pharmaceuticals from $465.00 to $550.00 and gave the stock a “buy” rating in a research report on Monday, June 17th. Finally, StockNews.com downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 5th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $485.91.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs sold 7,073 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total transaction of $3,168,704.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $17,920,000. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the sale, the chief marketing officer now directly owns 23,259 shares of the company’s stock, valued at approximately $11,088,728.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bruce I. Sachs sold 7,073 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the sale, the director now directly owns 40,000 shares in the company, valued at $17,920,000. The disclosure for this sale can be found here. Insiders have sold a total of 55,703 shares of company stock worth $26,615,855 in the last 90 days. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.